From Medscape Psychiatry

Coverage from the

17th Clinical Trials on Alzheimer's Disease (CTAD) Conference

October 29 - November 01, 2024; Madrid, Spain

October 29 - November 01, 2024 Madrid, Spain

Conference News

CTAD 2024 Personalized Neuromodulation Slows AD Progression
Medscape Medical News, November 12, 2024
CTAD 2024 Intranasal Insulin Drug Combo Promising for Alzheimer’s
Medscape Medical News, November 6, 2024
CTAD 2024 Leukemia Drug Shows Promise in Lewy Body Dementia
Medscape Medical News, November 5, 2024

CTAD 2024 Finger-Prick Test for Alzheimer’s Disease?
Medscape Medical News, November 1, 2024
CTAD 2024 Expert Guidance Issued for Real-World Use of Donanemab
Medscape Medical News, October 30, 2024

Medscape Psychiatry©

Popular News From CTAD 2023

Promising Phase 2 Results for Novel Oral Alzheimer's Drug An investigational dual PPAR agonist modifies Alzheimer's pathology and shows cognitive benefit in adults with mild-to-moderate disease and high plasma pTau-217 ratio, early data show.
Medscape Medical News, Oct 25, 2023
Natural Killer Cell Therapy Shows Promise in Alzheimer's Data from a small phase I study show significant clinical and biomarker activity of an investigational natural killer cell therapy in adults with AD, prompting a larger phase 2 trial.
Medscape Medical News, Nov 02, 2023
First-in-Class Regenerative Therapeutic for AD Promising Allopregnanolone has the potential to delay neurodegeneration in early Alzheimer's disease by promoting endogenous systems of renewal and repair, early testing shows.
Medscape Medical News, Oct 30, 2023

Previous Coverage

Related Resources

Alzheimer's Disease

All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.